Literature DB >> 3090971

[Congestive cardiomyopathy in addiction to clobenzorex, an anorexigenic drug].

P Cornaert, J Camblin, P Graux, B Anaye, A Dutoit, L Croccel.   

Abstract

Cardiac failure caused by high doses of amphetamine-like drugs is rare. We report a case of decompensated congestive cardiomyopathy occurring in a 29 year old woman addicted to clobenzorex (Dinintel). This patient had been taking 5 to 7 capsules per day for 5 years. No other cause of cardiac failure was detected. A rapid improvement was obtained by digitalis and diuretic therapy; no further episodes of cardiac failure were observed after one year. However, the drug could not be completely withdrawn and echocardiography has shown increasing left ventricular dilatation. The possible mechanisms of amphetamine induced myocardial toxicity are discussed and the analogy with the group of adrenergic cardiomyopathies is underlined.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3090971

Source DB:  PubMed          Journal:  Arch Mal Coeur Vaiss        ISSN: 0003-9683


  3 in total

Review 1.  Neurochemical regulators of food behavior for pharmacological treatment of obesity: current status and future prospects.

Authors:  Gayane Sargis Vardanyan; Hasmik Samvel Harutyunyan; Michail Iosif Aghajanov; Ruben Sargis Vardanyan
Journal:  Future Med Chem       Date:  2020-10-12       Impact factor: 3.808

2.  Drugs and dilated cardiomyopathies: A case/noncase study in the French PharmacoVigilance Database.

Authors:  Guillaume Montastruc; Sylvie Favreliere; Agnès Sommet; Atul Pathak; Maryse Lapeyre-Mestre; Marie-Christine Perault-Pochat; Jean-Louis Montastruc
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

3.  The Chronic Oral Administration of Clobenzorex or Amphetamine Decreases Motor Behavior and Induces Glial Activation in the Striatum Without Dopaminergic Degeneration.

Authors:  Grego David Apóstol Del Rosal; Ilhuicamina Daniel Limón; Isabel Martínez; Aleidy Patricio-Martínez
Journal:  Neurotox Res       Date:  2021-07-19       Impact factor: 3.911

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.